| Methods |
Blinding of randomisation: yes
Blinding of intervention: can't tell but probably impossible
Complete follow‐up: yes
Blinding of outcome measurement: can't tell |
| Participants |
Term infants.
Infants with birth asphyxia, gastrointerstinal pathology or haemolysis excluded. Infants of mothers with diabetes or who received corticosteroids or barbiturates excluded.
Qualifying SBR >239.
Fibreoptic (Wallaby) n=18, conventional (white) n=18, conventional (white and blue) n=18. |
| Interventions |
Fibreoptic: Wallaby at 8‐10 microwatts/cm2/nm (measured).
Conventional (white and blue): 4 True Light Duro‐Test 20 TH 12 TXC and 4 Philips TL 20 W/03T at 44 microwatts/ cm2/nm.
Convnetional (white): True Light Duro‐Test 20 TH 12 TXC at 6.5 microwatts/cm2/nm (measured). |
| Outcomes |
Absolute SBR at 24, 48 and 72 hours.
% reduction in SBR at 24, 48 and 72 hours.
Use of exchange transfusion. |
| Notes |
Data complete |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
